Stage III lung squamous cell carcinoma is a complex condition where cancer has spread beyond the lung but remains confined to the chest area. Treatment involves a combination of therapies designed to control disease progression, manage symptoms, and improve quality of life, with new approaches emerging from clinical research.

Understanding Treatment Goals for Stage III Lung Squamous Cell Carcinoma

When someone receives a diagnosis of stage III lung squamous cell carcinoma, the path forward involves careful planning and a combination of treatments. Stage III is what doctors call locally advanced disease, meaning the cancer has grown beyond its starting point in the lung but hasn’t yet traveled to distant organs like the liver or brain. This stage represents about one-third of all lung cancer diagnoses, and treatment approaches depend heavily on the exact location of tumors, which lymph nodes are involved, and the patient’s overall health.^[1]

The primary aim of treating stage III squamous cell lung cancer is to control the disease as much as possible, extend survival, and maintain the best possible quality of life. Because this stage sits between early and advanced cancer, doctors often take what they call a “maximalist attitude”—using every available tool to fight the disease. This might include surgery, radiation, chemotherapy, and increasingly, newer therapies like immunotherapy.^[4]

Unlike stage IV cancer, where the disease has spread throughout the body, stage III cancer is still considered potentially treatable with curative intent in some patients. However, the approach is rarely simple. Treatment decisions must be made by a team of specialists working together, including lung cancer surgeons, medical oncologists who prescribe chemotherapy and immunotherapy, and radiation oncologists. The exact sequence of treatments—what comes first, what follows—can vary significantly from patient to patient.^[4]

Stage III squamous cell carcinoma differs from other types of lung cancer in important ways. Squamous cell carcinoma typically starts in the center of the lungs, in the main airways, rather than in the outer edges. It is strongly linked to smoking—more so than any other type of non-small cell lung cancer. Approximately 80% of cases in men and 90% in women are associated with tobacco use. Other risk factors include exposure to asbestos, radon, and secondhand smoke.^[7]

Standard Treatment Approaches

The foundation of treating stage III squamous cell lung cancer rests on three main pillars: chemotherapy, radiation therapy, and surgery. How these are combined depends on whether the cancer is deemed “resectable”—meaning surgeons believe they can remove it safely and completely.

Combined Chemotherapy and Radiation (Chemoradiation)

For many patients with stage III disease, treatment begins with chemoradiation, which means receiving chemotherapy and radiation therapy at the same time. This combination is often the first step, particularly for patients whose tumors are not immediately suitable for surgery, or for those whose overall health makes surgery too risky. The chemotherapy drugs enhance the effects of radiation, making the treatment more effective than either therapy alone.^[11]

The most commonly used chemotherapy combination during chemoradiation includes cisplatin paired with etoposide. Cisplatin is a platinum-based drug that damages the DNA inside cancer cells, preventing them from dividing. Etoposide works by blocking an enzyme that cancer cells need to replicate. Other chemotherapy combinations used for stage III squamous cell carcinoma include cisplatin with vinorelbine, carboplatin with paclitaxel, and cisplatin with gemcitabine. Carboplatin is an alternative to cisplatin that causes fewer side effects, though it may be slightly less potent.^[11]

Radiation therapy for lung cancer uses high-energy beams to kill cancer cells. The treatment is carefully planned using CT scans to target the tumor and involved lymph nodes while sparing as much healthy lung tissue as possible. Patients typically receive radiation five days a week for several weeks. During this time, they continue taking chemotherapy drugs according to a schedule determined by their oncologist.^[10]

The side effects of chemoradiation can be significant but are usually manageable. Common problems include fatigue, which can be overwhelming at times; difficulty swallowing if radiation affects the esophagus; irritation and inflammation of the lung tissue, called pneumonitis; and reduced blood cell counts, which increase the risk of infection and bleeding. Nausea, loss of appetite, and hair loss may occur from the chemotherapy. Most side effects gradually improve after treatment ends, though some, like lung scarring, can persist.^[10]

Surgery for Stage III Disease

Surgery is most commonly considered for patients with stage IIIA disease, particularly if chemoradiation has successfully shrunk the tumor. The goal is to remove the cancer completely, along with affected lymph nodes, to reduce the chance of recurrence. Several surgical procedures may be used depending on the tumor’s location and size.^[11]

A lobectomy removes the entire lobe of the lung where the tumor is located. The right lung has three lobes, and the left has two; removing one lobe is the most common surgical approach. A bilobectomy removes two of the three lobes from the right lung when the cancer involves more than one lobe. In some cases, a pneumonectomy—removal of an entire lung—is necessary, though this is a major operation with a longer recovery and more limitations afterward.^[11]

A less extensive procedure called a sleeve resection removes a section of the bronchus (the main airway) containing the tumor, then reconnects the remaining parts. This preserves more lung tissue compared to a lobectomy. For tumors that have grown into the chest wall, bones, or nearby blood vessels, surgeons may perform an extended pulmonary resection, removing affected surrounding tissues to get clear margins around the cancer.^[11]

Not every patient with stage III squamous cell carcinoma is a candidate for surgery. Doctors consider the patient’s lung function, heart health, and overall fitness for a major operation. They also assess whether the cancer can be removed completely with negative margins—meaning no cancer cells are found at the edges of the removed tissue. For stage IIIB and IIIC disease, surgery is generally not recommended because the cancer has spread too extensively within the chest.^[11]

Chemotherapy Alone or After Surgery

Chemotherapy may be given before surgery to shrink tumors, making them easier to remove. It may also be given after surgery to eliminate any remaining cancer cells that are too small to see on scans. The decision depends on whether chemotherapy was already used during chemoradiation, how well the tumor responded, and the patient’s ability to tolerate additional treatment.^[11]

When chemotherapy is used alone without radiation—such as when a patient cannot tolerate radiation therapy—the same drug combinations are employed. Treatment typically involves cycles lasting three to four weeks, repeated for four to six cycles. Patients receive intravenous infusions in an outpatient setting, allowing them to return home the same day. Blood tests are performed regularly to monitor for side effects like low blood counts.^[11]

Treatment Being Tested in Clinical Trials

The landscape of stage III lung cancer treatment has been transformed in recent years by the introduction of immunotherapy and targeted therapies. These newer approaches are being studied intensively in clinical trials, and some have already become part of standard care in certain situations.

Immunotherapy in Stage III Disease

Immunotherapy drugs work by helping the immune system recognize and attack cancer cells. Unlike chemotherapy, which directly kills dividing cells, immunotherapy essentially removes the brakes that cancer uses to hide from immune detection. The most widely used immunotherapy drugs are called immune checkpoint inhibitors, and they have shown remarkable results in clinical trials for stage III lung cancer.^[14]

One of the major breakthroughs came from studies showing that giving immunotherapy after chemoradiation significantly improves survival. The drug durvalumab (brand name Imfinzi) was tested in a Phase III trial and found to help patients live longer without their cancer progressing. Durvalumab targets a protein called PD-L1 on cancer cells, preventing it from binding to the PD-1 receptor on immune cells. This allows immune cells to attack the tumor more effectively.^[14]

Based on these trial results, durvalumab is now commonly given as maintenance therapy after patients complete chemoradiation for stage III squamous cell carcinoma. Treatment typically continues for up to one year, with infusions given every two to four weeks. Common side effects include fatigue, cough, and immune-related problems such as inflammation of the lungs, liver, or thyroid gland. These side effects occur because the activated immune system can sometimes attack normal tissues.^[14]

Clinical trials are also exploring immunotherapy in other settings. Some studies are testing whether giving immunotherapy before surgery (called neoadjuvant therapy) can shrink tumors more effectively than chemotherapy alone, making them easier to remove and reducing the risk of recurrence. Early results have been promising, showing that tumors often shrink dramatically when immunotherapy is added to chemotherapy before surgery.^[14]

Targeted Therapies

Targeted therapies are drugs designed to attack specific genetic mutations or proteins that cancer cells depend on for growth. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapies are more precise and often cause fewer side effects. However, these treatments only work in patients whose tumors have specific genetic changes.^[11]

For squamous cell lung cancer, targeted therapy options are more limited than for lung adenocarcinoma, which often has genetic mutations that can be targeted. However, researchers have identified some mutations that occur in squamous cell carcinoma, and drugs are being tested to target them. One area of focus is mutations in the EGFR gene, which produces a protein called the epidermal growth factor receptor. This receptor sends signals that tell cancer cells to grow and divide. Drugs like erlotinib and gefitinib block EGFR, and while these are used primarily for adenocarcinoma, trials are exploring their role in squamous cell cancers with EGFR mutations.^[11]

Another target being studied is FGFR, or fibroblast growth factor receptor. Some squamous cell lung cancers have abnormalities in FGFR genes. Drugs that inhibit FGFR are in clinical trials, testing whether they can slow cancer growth in patients with these genetic changes. These trials are typically Phase II studies, meaning they are focused on determining whether the drug is effective and what dose should be used.^[11]

Before targeted therapy can be considered, patients undergo molecular testing (also called biomarker testing or genetic profiling) on their tumor tissue. This involves analyzing the cancer cells to look for specific mutations. The testing is done on tissue obtained during biopsy or surgery. Results take one to two weeks and guide treatment decisions. If a targetable mutation is found, the patient may be eligible for a clinical trial or, in some cases, an approved targeted drug.^[11]

Combination Approaches in Clinical Trials

Many current clinical trials are testing combinations of different treatment types to see if outcomes can be further improved. For example, some trials are combining immunotherapy with chemotherapy before surgery, then giving additional immunotherapy afterward. The rationale is that hitting the cancer with multiple approaches at different times might be more effective than any single strategy.^[14]

Researchers are also exploring whether adding targeted therapy to immunotherapy can enhance results. Since these drugs work through different mechanisms—one by blocking specific growth signals and the other by activating the immune system—combining them might provide complementary benefits. These studies are in earlier phases, typically Phase I or II, meaning they are still establishing safety and preliminary effectiveness.^[14]

Clinical trials for stage III lung squamous cell carcinoma are being conducted at major cancer centers across Europe, the United States, and other regions. Eligibility depends on factors like the exact stage of disease, previous treatments received, genetic characteristics of the tumor, and the patient’s overall health. Patients interested in clinical trials should discuss options with their oncology team, who can search databases of available studies and determine whether participation might be appropriate.^[4]

Most Common Treatment Methods

• Chemoradiation
  • Combination of chemotherapy and radiation therapy given simultaneously, often as initial treatment for stage III disease
  • Commonly uses cisplatin with etoposide, delivered over several weeks
  • Radiation targeted to tumor and affected lymph nodes, typically five days per week
  • May shrink tumors enough to make surgery possible
• Chemotherapy
  • Drugs that kill rapidly dividing cancer cells throughout the body
  • Common combinations include cisplatin with vinorelbine, carboplatin with paclitaxel, and cisplatin with gemcitabine
  • Given before surgery to shrink tumors, after surgery to eliminate remaining cells, or alone if surgery isn’t possible
  • Treatment cycles typically last three to four weeks, repeated four to six times
• Surgery
  • Lobectomy removes the lobe of lung containing the tumor
  • Pneumonectomy removes an entire lung in more extensive cases
  • Sleeve resection removes part of the bronchus while preserving lung tissue
  • Most often performed for stage IIIA disease after successful chemoradiation
  • Not typically recommended for stage IIIB or IIIC disease
• Immunotherapy
  • Drugs that help the immune system recognize and attack cancer cells
  • Durvalumab given as maintenance therapy after chemoradiation for up to one year
  • Blocks PD-L1 protein, allowing immune cells to attack tumors
  • Being tested in clinical trials before surgery and in combination with other treatments
• Targeted Therapy
  • Drugs targeting specific genetic mutations in cancer cells
  • EGFR inhibitors for tumors with EGFR mutations
  • FGFR inhibitors being tested in trials for tumors with FGFR abnormalities
  • Requires molecular testing of tumor tissue to identify targetable mutations
  • More limited options available for squamous cell carcinoma compared to adenocarcinoma